JP2019528291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528291A5 JP2019528291A5 JP2019510688A JP2019510688A JP2019528291A5 JP 2019528291 A5 JP2019528291 A5 JP 2019528291A5 JP 2019510688 A JP2019510688 A JP 2019510688A JP 2019510688 A JP2019510688 A JP 2019510688A JP 2019528291 A5 JP2019528291 A5 JP 2019528291A5
- Authority
- JP
- Japan
- Prior art keywords
- oxazole
- benzo
- oxadiazole
- amine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 78
- 150000001875 compounds Chemical class 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 125000003545 alkoxy group Chemical group 0.000 claims description 40
- 125000004122 cyclic group Chemical group 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 28
- 208000035143 Bacterial infection Diseases 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 17
- -1 cyano, hydroxyl Chemical group 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 150000002431 hydrogen Chemical group 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 125000002757 morpholinyl group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 241000194032 Enterococcus faecalis Species 0.000 claims description 7
- 241000194017 Streptococcus Species 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 241000588653 Neisseria Species 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 5
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 5
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 5
- 241000589884 Treponema pallidum Species 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 241000186046 Actinomyces Species 0.000 claims description 4
- 241000606125 Bacteroides Species 0.000 claims description 4
- 241000193163 Clostridioides difficile Species 0.000 claims description 4
- 241000193468 Clostridium perfringens Species 0.000 claims description 4
- 241000186216 Corynebacterium Species 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 4
- 241000194049 Streptococcus equinus Species 0.000 claims description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 241000122230 Acinetobacter junii Species 0.000 claims description 3
- 241000186041 Actinomyces israelii Species 0.000 claims description 3
- 241000589876 Campylobacter Species 0.000 claims description 3
- 241000193449 Clostridium tetani Species 0.000 claims description 3
- 241000186227 Corynebacterium diphtheriae Species 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- 241000194031 Enterococcus faecium Species 0.000 claims description 3
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 241000589248 Legionella Species 0.000 claims description 3
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 3
- 241000589902 Leptospira Species 0.000 claims description 3
- 241000186779 Listeria monocytogenes Species 0.000 claims description 3
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 3
- 241000186362 Mycobacterium leprae Species 0.000 claims description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 241000606856 Pasteurella multocida Species 0.000 claims description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 3
- 241001312524 Streptococcus viridans Species 0.000 claims description 3
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 claims description 3
- 241000193462 [Clostridium] innocuum Species 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 3
- 229940037467 helicobacter pylori Drugs 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229940051027 pasteurella multocida Drugs 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- FRNTUFQKHQMLSE-UHFFFAOYSA-N 1,3-benzoxazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=COC2=C1 FRNTUFQKHQMLSE-UHFFFAOYSA-N 0.000 claims description 2
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 claims description 2
- RAIDETWAVHBZPK-UHFFFAOYSA-N 1-[2-(1,3,4-oxadiazol-2-ylamino)-1,3-benzoxazol-6-yl]pyrrolidin-2-one Chemical compound O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)N1C(CCC1)=O RAIDETWAVHBZPK-UHFFFAOYSA-N 0.000 claims description 2
- HIJXDBIWKKEDAY-UHFFFAOYSA-N 2-(1,3,4-oxadiazol-2-yl)-3H-1,3-benzoxazole-2,6-diamine Chemical compound O1C(=NN=C1)C1(OC2=C(N1)C=CC(=C2)N)N HIJXDBIWKKEDAY-UHFFFAOYSA-N 0.000 claims description 2
- ZHRXZPHSEOBDCW-UHFFFAOYSA-N 2-(1,3,4-oxadiazol-2-ylamino)-1,3-benzoxazol-6-ol Chemical compound O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)O ZHRXZPHSEOBDCW-UHFFFAOYSA-N 0.000 claims description 2
- VUAYRVYSQOPQOQ-UHFFFAOYSA-N 2-(1,3,4-oxadiazol-2-ylamino)-1,3-benzoxazole-6-carboxylic acid Chemical compound O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)C(=O)O VUAYRVYSQOPQOQ-UHFFFAOYSA-N 0.000 claims description 2
- FPEGACXSUIACHC-UHFFFAOYSA-N 3h-oxadiazole-2-carboxylic acid Chemical compound OC(=O)N1NC=CO1 FPEGACXSUIACHC-UHFFFAOYSA-N 0.000 claims description 2
- NIUFVDQQKBARIY-UHFFFAOYSA-N 4-[(6-chloro-1,3-benzoxazol-2-yl)amino]-1,3-oxazole-2-carboxylic acid Chemical compound ClC1=CC2=C(N=C(O2)NC=2N=C(OC=2)C(=O)O)C=C1 NIUFVDQQKBARIY-UHFFFAOYSA-N 0.000 claims description 2
- NVAFYAACHPNJIF-UHFFFAOYSA-N 5-[(5-fluoro-1,3-benzoxazol-2-yl)amino]-1,3,4-oxadiazole-2-carbonitrile Chemical compound FC=1C=CC2=C(N=C(O2)NC2=NN=C(O2)C#N)C=1 NVAFYAACHPNJIF-UHFFFAOYSA-N 0.000 claims description 2
- UXXVLXFFAPWJQO-UHFFFAOYSA-N 5-[(5-fluoro-1,3-benzoxazol-2-yl)amino]-1,3,4-oxadiazole-2-carboxamide Chemical compound FC=1C=CC2=C(N=C(O2)NC2=NN=C(O2)C(=O)N)C=1 UXXVLXFFAPWJQO-UHFFFAOYSA-N 0.000 claims description 2
- BSSGPOJRXJVSBI-UHFFFAOYSA-N 5-[(6-chloro-1,3-benzoxazol-2-yl)amino]-1,3,4-oxadiazole-2-carbonitrile Chemical compound ClC1=CC2=C(N=C(O2)NC2=NN=C(O2)C#N)C=C1 BSSGPOJRXJVSBI-UHFFFAOYSA-N 0.000 claims description 2
- MGPPRGSIHDVBBK-UHFFFAOYSA-N 5-[(6-chloro-1,3-benzoxazol-2-yl)amino]-1,3,4-oxadiazole-2-carboxamide Chemical compound ClC1=CC2=C(N=C(O2)NC2=NN=C(O2)C(=O)N)C=C1 MGPPRGSIHDVBBK-UHFFFAOYSA-N 0.000 claims description 2
- WSSDTWAPGLKDCQ-UHFFFAOYSA-N 5-[(6-fluoro-1,3-benzoxazol-2-yl)amino]-1,3,4-oxadiazole-2-carboxamide Chemical compound FC1=CC2=C(N=C(O2)NC2=NN=C(O2)C(=O)N)C=C1 WSSDTWAPGLKDCQ-UHFFFAOYSA-N 0.000 claims description 2
- AZMGETFUDRUHCX-UHFFFAOYSA-N 5-chloro-6-methoxy-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC=1C(=CC2=C(N=C(O2)NC=2OC=NN=2)C=1)OC AZMGETFUDRUHCX-UHFFFAOYSA-N 0.000 claims description 2
- BBZSIWQJQGZBSA-UHFFFAOYSA-N 5-chloro-6-methyl-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC=1C(=CC2=C(N=C(O2)NC=2OC=NN=2)C=1)C BBZSIWQJQGZBSA-UHFFFAOYSA-N 0.000 claims description 2
- SYRSOQLBQJAHGZ-UHFFFAOYSA-N 5-chloro-N-(1,3,4-oxadiazol-2-yl)-6-(trifluoromethoxy)-1,3-benzoxazol-2-amine Chemical compound ClC=1C(=CC2=C(N=C(O2)NC=2OC=NN=2)C=1)OC(F)(F)F SYRSOQLBQJAHGZ-UHFFFAOYSA-N 0.000 claims description 2
- UVMFTQOFGZTLLF-UHFFFAOYSA-N 5-chloro-N-(1,3-thiazol-4-yl)-1,3-benzoxazol-2-amine Chemical compound ClC=1C=CC2=C(N=C(O2)NC=2N=CSC=2)C=1 UVMFTQOFGZTLLF-UHFFFAOYSA-N 0.000 claims description 2
- CYJUNIDNMCKMEI-UHFFFAOYSA-N 5-fluoro-6-methoxy-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound FC=1C(=CC2=C(N=C(O2)NC=2OC=NN=2)C=1)OC CYJUNIDNMCKMEI-UHFFFAOYSA-N 0.000 claims description 2
- SBILZBCLSVWOTH-UHFFFAOYSA-N 5-fluoro-6-methyl-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound FC=1C(=CC2=C(N=C(O2)NC=2OC=NN=2)C=1)C SBILZBCLSVWOTH-UHFFFAOYSA-N 0.000 claims description 2
- NZSZXMBTYGMBEV-UHFFFAOYSA-N 5-fluoro-N-(1,3,4-oxadiazol-2-yl)-6-(trifluoromethoxy)-1,3-benzoxazol-2-amine Chemical compound FC=1C(=CC2=C(N=C(O2)NC=2OC=NN=2)C=1)OC(F)(F)F NZSZXMBTYGMBEV-UHFFFAOYSA-N 0.000 claims description 2
- UZNJREMMYCBNHT-UHFFFAOYSA-N 5-methyl-N-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound CC1=NN=C(S1)NC1=NC2=C(N1)C=CC(=C2)C(F)(F)F UZNJREMMYCBNHT-UHFFFAOYSA-N 0.000 claims description 2
- ZOEARHYZLYQFNW-UHFFFAOYSA-N 6-(2-methoxyethoxy)-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound COCCOC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1 ZOEARHYZLYQFNW-UHFFFAOYSA-N 0.000 claims description 2
- GZSPPESWVWTQNX-UHFFFAOYSA-N 6-bromo-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound BrC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1 GZSPPESWVWTQNX-UHFFFAOYSA-N 0.000 claims description 2
- ICRQUQUHPZRAFR-UHFFFAOYSA-N 6-chloro-4-fluoro-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC=NN=2)C(=C1)F ICRQUQUHPZRAFR-UHFFFAOYSA-N 0.000 claims description 2
- APTIOJOQJKSQIL-UHFFFAOYSA-N 6-chloro-4-methyl-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC=NN=2)C(=C1)C APTIOJOQJKSQIL-UHFFFAOYSA-N 0.000 claims description 2
- FRZLFCVAZSOOJH-UHFFFAOYSA-N 6-chloro-5-methoxy-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1OC FRZLFCVAZSOOJH-UHFFFAOYSA-N 0.000 claims description 2
- GFJZRLUYMXDHSV-UHFFFAOYSA-N 6-chloro-5-methyl-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1C GFJZRLUYMXDHSV-UHFFFAOYSA-N 0.000 claims description 2
- SWWZJVJEKIFQND-UHFFFAOYSA-N 6-chloro-N-(1,2-oxazol-4-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2C=NOC=2)C=C1 SWWZJVJEKIFQND-UHFFFAOYSA-N 0.000 claims description 2
- GHKJBJUTXROIFY-UHFFFAOYSA-N 6-chloro-N-(1,2-thiazol-3-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC2=NSC=C2)C=C1 GHKJBJUTXROIFY-UHFFFAOYSA-N 0.000 claims description 2
- TXPAXUWKOQXHGO-UHFFFAOYSA-N 6-chloro-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1 TXPAXUWKOQXHGO-UHFFFAOYSA-N 0.000 claims description 2
- MPVYLFKKLSJBAI-UHFFFAOYSA-N 6-chloro-N-(1,3,4-oxadiazol-2-yl)-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1OC(F)(F)F MPVYLFKKLSJBAI-UHFFFAOYSA-N 0.000 claims description 2
- UOIAYRCVJSHALK-UHFFFAOYSA-N 6-chloro-N-(1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1C(F)(F)F UOIAYRCVJSHALK-UHFFFAOYSA-N 0.000 claims description 2
- BMJJHTNLIQKIJT-UHFFFAOYSA-N 6-chloro-N-(1,3,4-oxadiazol-2-yl)-[1,3]oxazolo[4,5-b]pyridin-2-amine Chemical compound ClC=1C=C2C(=NC=1)N=C(O2)NC=1OC=NN=1 BMJJHTNLIQKIJT-UHFFFAOYSA-N 0.000 claims description 2
- IWPQADCWQUWAEA-UHFFFAOYSA-N 6-chloro-N-(1,3-oxazol-4-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2N=COC=2)C=C1 IWPQADCWQUWAEA-UHFFFAOYSA-N 0.000 claims description 2
- QJTBXESERCOJPW-UHFFFAOYSA-N 6-chloro-N-(1H-1,2,4-triazol-5-yl)-5-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC2=NN=CN2)C=C1C(F)(F)F QJTBXESERCOJPW-UHFFFAOYSA-N 0.000 claims description 2
- GOLYBCJZAOQKKJ-UHFFFAOYSA-N 6-chloro-N-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC(=NN=2)C2CC2)C=C1 GOLYBCJZAOQKKJ-UHFFFAOYSA-N 0.000 claims description 2
- KOUPDEUQDRFBBH-UHFFFAOYSA-N 6-chloro-N-(5-ethynyl-1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC(=NN=2)C#C)C=C1 KOUPDEUQDRFBBH-UHFFFAOYSA-N 0.000 claims description 2
- WEAJXWVRFSSZOJ-UHFFFAOYSA-N 6-chloro-N-(5-methyl-1,2-oxazol-3-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC2=NOC(=C2)C)C=C1 WEAJXWVRFSSZOJ-UHFFFAOYSA-N 0.000 claims description 2
- WRJYZFMFUKNYLQ-UHFFFAOYSA-N 6-chloro-N-(5-propan-2-yl-1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC(=NN=2)C(C)C)C=C1 WRJYZFMFUKNYLQ-UHFFFAOYSA-N 0.000 claims description 2
- WBBNJVBDLWVWBD-UHFFFAOYSA-N 6-chloro-N-[4-(2-methoxyethyl)-5-methyl-1,2,4-triazol-3-yl]-5-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC2=NN=C(N2CCOC)C)C=C1C(F)(F)F WBBNJVBDLWVWBD-UHFFFAOYSA-N 0.000 claims description 2
- KIAXADQJYUQDKO-UHFFFAOYSA-N 6-chloro-N-[5-(oxolan-2-yl)-1,3,4-oxadiazol-2-yl]-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC(=NN=2)C2OCCC2)C=C1 KIAXADQJYUQDKO-UHFFFAOYSA-N 0.000 claims description 2
- JWOFTIIBCMOCHV-UHFFFAOYSA-N 6-chloro-N-[5-(oxolan-3-yl)-1,3,4-oxadiazol-2-yl]-1,3-benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)NC=2OC(=NN=2)C2COCC2)C=C1 JWOFTIIBCMOCHV-UHFFFAOYSA-N 0.000 claims description 2
- QDXJVLXSWHRNIC-UHFFFAOYSA-N 6-cyclopropyl-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound C1(CC1)C1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1 QDXJVLXSWHRNIC-UHFFFAOYSA-N 0.000 claims description 2
- XPIRTRAOZKDMPX-UHFFFAOYSA-N 6-fluoro-5-methoxy-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound FC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1OC XPIRTRAOZKDMPX-UHFFFAOYSA-N 0.000 claims description 2
- ZJLBDPLSLDQYLJ-UHFFFAOYSA-N 6-fluoro-5-methyl-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound FC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1C ZJLBDPLSLDQYLJ-UHFFFAOYSA-N 0.000 claims description 2
- SZVQTWSATDRJGI-UHFFFAOYSA-N 6-fluoro-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound FC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1 SZVQTWSATDRJGI-UHFFFAOYSA-N 0.000 claims description 2
- UCJUHBIRSSFGBX-UHFFFAOYSA-N 6-fluoro-N-(1,3,4-oxadiazol-2-yl)-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine Chemical compound FC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1OC(F)(F)F UCJUHBIRSSFGBX-UHFFFAOYSA-N 0.000 claims description 2
- GKGQBEWTELBRMI-UHFFFAOYSA-N 6-methoxy-5-methyl-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound COC1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1C GKGQBEWTELBRMI-UHFFFAOYSA-N 0.000 claims description 2
- RYGFPXZWRXVDHM-UHFFFAOYSA-N 6-nitro-N-(1,3,4-oxadiazol-2-yl)-1,3-benzoxazol-2-amine Chemical compound [N+](=O)([O-])C1=CC2=C(N=C(O2)NC=2OC=NN=2)C=C1 RYGFPXZWRXVDHM-UHFFFAOYSA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 2
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 241000193388 Bacillus thuringiensis Species 0.000 claims description 2
- 241000589968 Borrelia Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- FFRXWFVWOBOZMC-UHFFFAOYSA-N FC1=CC2=C(N=C(O2)NC2=NN=C(O2)C#N)C=C1 Chemical compound FC1=CC2=C(N=C(O2)NC2=NN=C(O2)C#N)C=C1 FFRXWFVWOBOZMC-UHFFFAOYSA-N 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 241000186367 Mycobacterium avium Species 0.000 claims description 2
- 241000187484 Mycobacterium gordonae Species 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- FCWSDRZHBABIBX-UHFFFAOYSA-N N-(1,2-oxazol-3-yl)-5-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound FC(F)(F)c1ccc2oc(Nc3ccon3)nc2c1 FCWSDRZHBABIBX-UHFFFAOYSA-N 0.000 claims description 2
- GIZHGYPJRVDJRU-UHFFFAOYSA-N N-(1,3,4-oxadiazol-2-yl)-6-(trifluoromethoxy)-1,3-benzoxazol-2-amine Chemical compound O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)OC(F)(F)F GIZHGYPJRVDJRU-UHFFFAOYSA-N 0.000 claims description 2
- GMSNJVKNGUJVQV-UHFFFAOYSA-N N-(1,3,4-oxadiazol-2-yl)-6-propan-2-yl-1,3-benzoxazol-2-amine Chemical compound CC(C)c1ccc2nc(Nc3nnco3)oc2c1 GMSNJVKNGUJVQV-UHFFFAOYSA-N 0.000 claims description 2
- BUMUFHDANPFXBU-UHFFFAOYSA-N N-(1,3,4-oxadiazol-2-yl)-6-propan-2-yloxy-1,3-benzoxazol-2-amine Chemical compound CC(C)Oc1ccc2nc(Nc3nnco3)oc2c1 BUMUFHDANPFXBU-UHFFFAOYSA-N 0.000 claims description 2
- ZPAAZWIIWXGINR-UHFFFAOYSA-N N-(1,3,4-oxadiazol-2-yl)-6-pyrrolidin-1-yl-1,3-benzoxazol-2-amine Chemical compound O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)N1CCCC1 ZPAAZWIIWXGINR-UHFFFAOYSA-N 0.000 claims description 2
- CURCXOCCLNUTRT-UHFFFAOYSA-N N-(1,3,4-thiadiazol-2-yl)-5-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound S1C(=NN=C1)NC=1OC2=C(N=1)C=C(C=C2)C(F)(F)F CURCXOCCLNUTRT-UHFFFAOYSA-N 0.000 claims description 2
- GRWAXWGVABBEHE-UHFFFAOYSA-N N-(1,3-benzoxazol-2-yl)-6-(trifluoromethyl)-[1,3]oxazolo[4,5-c]pyridin-2-amine Chemical compound O1C(=NC2=C1C=CC=C2)NC=1OC2=C(C=NC(=C2)C(F)(F)F)N=1 GRWAXWGVABBEHE-UHFFFAOYSA-N 0.000 claims description 2
- ZNEDFFWONJGSIY-UHFFFAOYSA-N N-(1,3-thiazol-2-yl)-5-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound S1C(=NC=C1)NC=1OC2=C(N=1)C=C(C=C2)C(F)(F)F ZNEDFFWONJGSIY-UHFFFAOYSA-N 0.000 claims description 2
- XALKKKASDZWBPH-UHFFFAOYSA-N N-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-6-(trifluoromethyl)-[1,3]oxazolo[4,5-c]pyridin-2-amine Chemical compound C1(CC1)C1=NN=C(O1)NC=1OC2=C(C=NC(=C2)C(F)(F)F)N=1 XALKKKASDZWBPH-UHFFFAOYSA-N 0.000 claims description 2
- AWNDJUIQELWNFL-UHFFFAOYSA-N N-(5-methyl-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound CC1=NN=C(O1)NC=1OC2=C(N=1)C=C(C=C2)C(F)(F)F AWNDJUIQELWNFL-UHFFFAOYSA-N 0.000 claims description 2
- CQMFDCKYWBFZEO-UHFFFAOYSA-N N-(5-piperidin-1-yl-1,3-thiazol-2-yl)-6-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound N1(CCCCC1)C1=CN=C(S1)NC=1OC2=C(N=1)C=CC(=C2)C(F)(F)F CQMFDCKYWBFZEO-UHFFFAOYSA-N 0.000 claims description 2
- PFFKNNOUEXXKCM-UHFFFAOYSA-N N-[5-(pyrrolidin-1-ylmethyl)-1,3,4-oxadiazol-2-yl]-5-(trifluoromethyl)-1,3-benzoxazol-2-amine Chemical compound N1(CCCC1)CC1=NN=C(O1)NC=1OC2=C(N=1)C=C(C=C2)C(F)(F)F PFFKNNOUEXXKCM-UHFFFAOYSA-N 0.000 claims description 2
- SYUPOMUEBLOPHK-UHFFFAOYSA-N N-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1,3,4-oxadiazol-2-amine Chemical compound FC(C1=CC2=C(NC(=N2)NC=2OC=NN=2)C=C1)(F)F SYUPOMUEBLOPHK-UHFFFAOYSA-N 0.000 claims description 2
- OHMRQEYBHBXECC-UHFFFAOYSA-N N-methyl-N-[2-(1,3,4-oxadiazol-2-ylamino)-1,3-benzoxazol-6-yl]acetamide Chemical compound O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)N(C(C)=O)C OHMRQEYBHBXECC-UHFFFAOYSA-N 0.000 claims description 2
- JJHQTOVLDPQSPP-UHFFFAOYSA-N N1(CCCC1)CC=1NC(=NN=1)NC=1OC2=C(N=1)C=C(C=C2)C(F)(F)F Chemical compound N1(CCCC1)CC=1NC(=NN=1)NC=1OC2=C(N=1)C=C(C=C2)C(F)(F)F JJHQTOVLDPQSPP-UHFFFAOYSA-N 0.000 claims description 2
- RIOVMZAGUXIZDW-UHFFFAOYSA-N O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)N1CCCCC1 Chemical compound O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)N1CCCCC1 RIOVMZAGUXIZDW-UHFFFAOYSA-N 0.000 claims description 2
- 241000606701 Rickettsia Species 0.000 claims description 2
- LQWBWDKULCVOKS-UHFFFAOYSA-N [2-(1,3,4-oxadiazol-2-ylamino)-1,3-benzoxazol-6-yl]methanol Chemical compound O1C(=NN=C1)NC=1OC2=C(N=1)C=CC(=C2)CO LQWBWDKULCVOKS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- 229940065181 bacillus anthracis Drugs 0.000 claims description 2
- 229940097012 bacillus thuringiensis Drugs 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- IAOZHJBPEMIGGM-UHFFFAOYSA-N ethyl 5-[(6-chloro-1,3-benzoxazol-2-yl)amino]-1,2,4-oxadiazole-3-carboxylate Chemical compound ClC1=CC2=C(N=C(O2)NC2=NC(=NO2)C(=O)OCC)C=C1 IAOZHJBPEMIGGM-UHFFFAOYSA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims 2
- 241000192035 Peptostreptococcus anaerobius Species 0.000 claims 2
- 241001478880 Streptobacillus moniliformis Species 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 claims 2
- 241000606124 Bacteroides fragilis Species 0.000 claims 1
- 241000589969 Borreliella burgdorferi Species 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 241000186364 Mycobacterium intracellulare Species 0.000 claims 1
- 208000024949 Swine Erysipelas Diseases 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 230000001358 anti-chlamydial effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 230000004224 protection Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000700601 Moniliformis Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1614314.1 | 2016-08-22 | ||
| GBGB1614314.1A GB201614314D0 (en) | 2016-08-22 | 2016-08-22 | Antibiotic compounds |
| PCT/GB2017/052478 WO2018037223A1 (en) | 2016-08-22 | 2017-08-22 | Antibiotic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528291A JP2019528291A (ja) | 2019-10-10 |
| JP2019528291A5 true JP2019528291A5 (enExample) | 2020-10-01 |
Family
ID=57045563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510688A Withdrawn JP2019528291A (ja) | 2016-08-22 | 2017-08-22 | 抗生化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190194179A1 (enExample) |
| EP (1) | EP3500567A1 (enExample) |
| JP (1) | JP2019528291A (enExample) |
| KR (1) | KR20190046894A (enExample) |
| CN (1) | CN109923111A (enExample) |
| AU (1) | AU2017316742A1 (enExample) |
| BR (1) | BR112019003427A2 (enExample) |
| CA (1) | CA3034000A1 (enExample) |
| CO (1) | CO2019002624A2 (enExample) |
| EA (1) | EA201990551A1 (enExample) |
| GB (1) | GB201614314D0 (enExample) |
| MX (1) | MX2019001978A (enExample) |
| PH (1) | PH12019500360A1 (enExample) |
| SG (1) | SG11201901374WA (enExample) |
| WO (1) | WO2018037223A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL282036B2 (en) | 2018-10-11 | 2024-03-01 | Bayer Ag | Process for preparing imidazole derivatives |
| EP3636645A1 (de) | 2018-10-11 | 2020-04-15 | Bayer Aktiengesellschaft | Verfahren zur herstellung schwefel-substituierter pyridinderivate |
| TWI841671B (zh) | 2019-01-24 | 2024-05-11 | 日商第一三共股份有限公司 | 具有取代基之脲化合物 |
| US20220125763A1 (en) | 2019-02-22 | 2022-04-28 | Anifera Limited | Compositions providing enhanced antibacterial activity against gram-positive bacteria and use thereof |
| CN111808093B (zh) * | 2019-04-12 | 2023-05-16 | 中国医学科学院医药生物技术研究所 | 一种新德里金属-β-内酰胺酶-1抑制剂 |
| CN113874074B (zh) * | 2019-04-12 | 2024-11-01 | 米托布里奇公司 | Hmox1诱导剂 |
| WO2022108354A1 (ko) * | 2020-11-19 | 2022-05-27 | 주식회사 에이엔제이사이언스 | 신규 화합물, 이의 제조방법 및 이를 포함하는 항생제 조성물 |
| CN113185475A (zh) * | 2021-04-29 | 2021-07-30 | 江苏永凯化学有限公司 | 一种高效低污染的精恶唑禾草灵生产工艺 |
| KR20240016304A (ko) * | 2021-05-31 | 2024-02-06 | 장슈 야홍 메디텍 코퍼레이션 리미티드 | 7-니트로-8-하이드록시퀴놀린 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| KR102754999B1 (ko) * | 2022-01-06 | 2025-01-21 | 충남대학교산학협력단 | 신규한 화합물 및 이를 포함하는 결핵균 또는 비결핵항산균 감염질환 치료용 약제학적 조성물 |
| AU2022461667A1 (en) * | 2022-06-01 | 2024-11-28 | KUDA Therapeutics, Inc. | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of hif-1/2a pathway inhibition, and induction of ferroptosis |
| EP4634175A1 (en) * | 2022-12-16 | 2025-10-22 | Immvention Therapeutix, Inc. | Benzimidazole derivatives |
| KR102840252B1 (ko) * | 2023-04-27 | 2025-07-30 | 한국화학연구원 | 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| CN117003710A (zh) * | 2023-07-19 | 2023-11-07 | 镇江先锋植保科技有限公司 | 一种2-巯基-6-氯苯并恶唑的制备方法 |
| WO2025050125A1 (en) * | 2023-09-01 | 2025-03-06 | Immvention Therapeutix | Substituted benzoxazolylamino benzoxazoles |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604217B2 (en) * | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| JP5786402B2 (ja) * | 2011-03-29 | 2015-09-30 | コニカミノルタ株式会社 | 光学フィルム、及びそれを用いた偏光板、液晶表示装置 |
| WO2016039939A1 (en) * | 2014-09-09 | 2016-03-17 | Ptc Therapeutics, Inc. | Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds |
-
2016
- 2016-08-22 GB GBGB1614314.1A patent/GB201614314D0/en not_active Ceased
-
2017
- 2017-08-22 KR KR1020197008269A patent/KR20190046894A/ko not_active Withdrawn
- 2017-08-22 WO PCT/GB2017/052478 patent/WO2018037223A1/en not_active Ceased
- 2017-08-22 MX MX2019001978A patent/MX2019001978A/es unknown
- 2017-08-22 EP EP17761308.0A patent/EP3500567A1/en not_active Withdrawn
- 2017-08-22 CA CA3034000A patent/CA3034000A1/en not_active Abandoned
- 2017-08-22 US US16/327,286 patent/US20190194179A1/en not_active Abandoned
- 2017-08-22 EA EA201990551A patent/EA201990551A1/ru unknown
- 2017-08-22 AU AU2017316742A patent/AU2017316742A1/en not_active Withdrawn
- 2017-08-22 BR BR112019003427-7A patent/BR112019003427A2/pt not_active Application Discontinuation
- 2017-08-22 JP JP2019510688A patent/JP2019528291A/ja not_active Withdrawn
- 2017-08-22 SG SG11201901374WA patent/SG11201901374WA/en unknown
- 2017-08-22 CN CN201780063473.8A patent/CN109923111A/zh active Pending
-
2019
- 2019-02-20 PH PH12019500360A patent/PH12019500360A1/en unknown
- 2019-03-21 CO CONC2019/0002624A patent/CO2019002624A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528291A5 (enExample) | ||
| US20190194179A1 (en) | Antibiotic compounds | |
| TW583184B (en) | A thiazine oxazolidinone useful as antimicrobial | |
| KR100927864B1 (ko) | 이원적 작용 항생제 | |
| ES2248633T3 (es) | Antibioticos oxazolidinona que contienen biciclo (3,1,o)hexano y derivados de los mismos. | |
| JP2009503024A5 (enExample) | ||
| JP2005520815A (ja) | 二環式複素環式の置換されたフェニルオキサゾリジノン抗細菌剤、関連組成物および方法 | |
| JP2003516404A (ja) | 抗細菌性の複素二環式の置換フェニルオキサゾリジノン類 | |
| CA2648157A1 (en) | 1-alkyl-5-aryl-3-arylamino-1h-1,2,4-triazoles as positive allosteric modulators of the alpha 7 receptor | |
| CN108135887A (zh) | 噁唑烷酮化合物及其作为抗菌剂的使用方法 | |
| JP2013542204A (ja) | 細菌トポイソメラーゼｉｉ阻害性２−エチルカルバモイルアミノ−１，３−ベンゾチアゾール−５−イル類 | |
| KR20110091504A (ko) | 퀴놀론 화합물의 제조 방법 | |
| PE20240239A1 (es) | Compuestos heterociclicos | |
| JP2008507539A5 (enExample) | ||
| HRP20210484T1 (hr) | Antimikrobna sredstva koja se temelje na imidazolu | |
| JP2009503025A5 (enExample) | ||
| EP0918770A1 (en) | Pyridyl-piperazinyl-phenyl-oxazolidinone derivatives and their use as antibacterials | |
| US6297242B1 (en) | N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof | |
| AU2014239965A1 (en) | Methods of treating infections in overweight and obese patients using antibiotics | |
| AU2006263880A1 (en) | Oxazolidinone derivatives and use thereof as antibiotics | |
| Riedl et al. | Recent developments with oxazolidinone antibiotics | |
| IL275817B2 (en) | Tricyclic compounds, compositions and medicinal applications thereof | |
| JP2009503021A5 (enExample) | ||
| JP2009523764A5 (enExample) | ||
| JP2019515003A5 (enExample) |